Tedizolid (CAT: I005141) is an oxazolidinone antibiotic used for the treatment of bacterial infections. It is a second-generation derivative of linezolid with improved pharmacokinetic properties. Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically targeting the 23S rRNA. It exhibits potent activity against a broad spectrum of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). Tedizolid has been approved for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.
| Catalog Number | I005141 |
| CAS Number | 856866-72-3 |
| Synonyms | (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one |
| Molecular Formula | C17H15FN6O3 |
| Purity | 98 |
| Target | Antibiotic |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| Overview of Clinical Research | Torezolid is an ribosomal protein inhibitor. <span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Tedizolid licensed to Nabriva Therapeutics in USA.</span></span></span> |
| IC50 | 8.7 μM(MAO-A); 5.7 μM(MAO-B) |
| IUPAC Name | (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one |
| InChI | InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1 |
| InChIKey | XFALPSLJIHVRKE-GFCCVEGCSA-N |
| SMILES | CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F |
| Reference | 1: Durkin MJ, Corey GR. New developments in the management of severe skin and deep skin structure infections – focus on tedizolid. Ther Clin Risk Manag. 2015 May 22;11:857-62. doi: 10.2147/TCRM.S64553. eCollection 2015. Review. PubMed PMID: 26045667; PubMed Central PMCID: PMC4447168.<br /> |
